Julia M.W. Gee

17.8k total citations · 1 hit paper
243 papers, 13.4k citations indexed

About

Julia M.W. Gee is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Julia M.W. Gee has authored 243 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 104 papers in Genetics and 86 papers in Molecular Biology. Recurrent topics in Julia M.W. Gee's work include Estrogen and related hormone effects (94 papers), HER2/EGFR in Cancer Research (68 papers) and Marine Biology and Ecology Research (25 papers). Julia M.W. Gee is often cited by papers focused on Estrogen and related hormone effects (94 papers), HER2/EGFR in Cancer Research (68 papers) and Marine Biology and Ecology Research (25 papers). Julia M.W. Gee collaborates with scholars based in United Kingdom, United States and Australia. Julia M.W. Gee's co-authors include Robert I. Nicholson, M. E. Harper, Ian O. Ellis, Denise Barrow, R.M. Warwick, J.F.R. Robertson, Janice M. Knowlden, Iain R. Hutcheson, Ian T. Johnson and Helen E. Jones and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Julia M.W. Gee

239 papers receiving 12.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR and cancer prognosis

2001 1.7k citations Robert I. Nicholson, Julia M.W. Gee et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by Julia M.W. Gee

Since Specialization

Citations

This map shows the geographic impact of Julia M.W. Gee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia M.W. Gee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia M.W. Gee more than expected).

Fields of papers citing papers by Julia M.W. Gee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia M.W. Gee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia M.W. Gee. The network helps show where Julia M.W. Gee may publish in the future.

Co-authorship network of co-authors of Julia M.W. Gee

This figure shows the co-authorship network connecting the top 25 collaborators of Julia M.W. Gee. A scholar is included among the top collaborators of Julia M.W. Gee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia M.W. Gee. Julia M.W. Gee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors 2022 ·European Journal of Medicinal Chemistry ·(unknown), Denise Barrow, Julia M.W. Gee, (unknown), Paul Foster, Claire Simons	8
2	Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP 2018 ·Clinical Cancer Research ·(unknown), Andreia Silva, Tim Robinson, Angélica Santiago-Gómez, Bruno M. Simões, Michael W. Becker, Iduna Fichtner, Ladislav Anděra, (unknown), Christine M. Morris, Peter Barrett‐Lee, Fouad Alchami, Marco Piva, María dM Vivanco, Robert B. Clarke, Julia M.W. Gee, Richard Clarkson	42
3	Long-range regulators of the lncRNAHOTAIRenhance its prognostic potential in breast cancer 2016 ·Human Molecular Genetics ·Michael J. G. Milevskiy, Fares Al‐Ejeh, Jodi M. Saunus, Korinne Northwood, Peter J. Bailey, Joshua A. Betts, Amy E. McCart Reed, Kenneth P. Nephew, Andrew Stone, Julia M.W. Gee, Dennis H. Dowhan, Eloïse Dray, Annette M. Shewan, Juliet D. French, Stacey L. Edwards, Susan J. Clark, Sunil R. Lakhani, Melissa A. Brown	58
4	A Good Drug Made Better: The Fulvestrant Dose-Response Story 2014 ·Clinical Breast Cancer ·J.F.R. Robertson, Justin P.O. Lindemann, Sally Garnett, Elizabeth J. Anderson, Robert I. Nicholson, Irene Kuter, Julia M.W. Gee	54
5	BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer 2013 ·Molecular Cancer Therapeutics ·Andrew Stone, Mark J. Cowley, Fátima Valdés‐Mora, Rachael A. McCloy, C. Marcelo Sergio, David Gallego‐Ortega, C. Elizabeth Caldon, Christopher J. Ormandy, Andrew V. Biankin, Julia M.W. Gee, Robert I. Nicholson, Cristin G. Print, Susan J. Clark, Elizabeth A. Musgrove	39
6	Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells 2012 ·Molecular Cancer Therapeutics ·C. Elizabeth Caldon, C. Marcelo Sergio, Jian Kang, Anita Muthukaruppan, (unknown), Andrew Stone, Jane Barraclough, (unknown), Michael A. Black, Lance D. Miller, Julia M.W. Gee, (unknown), Robert L. Sutherland, Cristin G. Print, Elizabeth A. Musgrove	125
7	Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance 2011 ·Hormone Molecular Biology and Clinical Investigation ·Julia M.W. Gee, Robert I. Nicholson, Denise Barrow, Carol M. Dutkowski, Lindy Goddard, Nicola Jordan, Richard A. McClelland, Janice M. Knowlden, Hayley E. Francies, Stephen Hiscox, Iain R. Hutcheson	6
8	Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival 2008 ·Cancer Research ·Jennifer Law, Golareh Habibi, Kaiji Hu, Hamid Masoudi, (unknown), Anna L. Stratford, Eugene Park, Julia M.W. Gee, Pauline Finlay, Helen E. Jones, Robert I. Nicholson, Joan M. Carboni, Marco M. Gottardis, Michaël Pollak, Sandra E. Dunn	339
9	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells 2005 ·Breast Cancer Research and Treatment ·Stephen Hiscox, L. Morgan, Tim P. Green, Denise Barrow, Julia M.W. Gee, Robert I. Nicholson	201
10	Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract] 2004 ·Breast Cancer Research and Treatment ·Iain R. Hutcheson, Julia M.W. Gee, Denise Barrow, Helen E. Jones, A. E. Wakeling, Robert I. Nicholson	2
11	Characterization of ER alpha and cofactor recruitment during fulvestrant treatment and resistance in breast cancer using chromatin immunoprecipitation [Abstract] 2004 ·Breast Cancer Research and Treatment ·(unknown), Julia M.W. Gee, A. E. Wakeling, Robert I. Nicholson	1
12	Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells 2003 ·Endocrinology ·Janice M. Knowlden, Iain R. Hutcheson, Helen E. Jones, Tracie‐Ann Madden, Julia M.W. Gee, M. E. Harper, Denise Barrow, Alan E. Wakeling, Robert I. Nicholson	432
13	Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors 2002 ·Breast Cancer Research ·Julia M.W. Gee	2
14	TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence 2001 ·International Journal of Cancer ·E Glynne-Jones, M. E. Harper, Liam T. Seery, (unknown), Ian E. Anglin, Helen Morgan, KM Taylor, Julia M.W. Gee, Robert I. Nicholson	50
15	Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer 2001 ·Breast Cancer Research and Treatment ·F.S. Kenny, Peter C. Willsher, Julia M.W. Gee, Robert I. Nicholson, Sarah E. Pinder, Ian O. Ellis, J.F.R. Robertson	32
16	Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation withGRB2 expression 2000 ·International Journal of Cancer ·(unknown), A. Jayne Crew, Julia M.W. Gee, Rina Hui, Roger W. Blamey, J.F.R. Robertson, Robert I. Nicholson, Robert L. Sutherland, Roger J. Daly	55
17	BRCA1 expression levels predict distant metastasis of sporadic breast cancers 1999 ·International Journal of Cancer ·Liam T. Seery, Janice M. Knowlden, Julia M.W. Gee, J.F.R. Robertson, (unknown), Ian O. Ellis, Robert I. Nicholson	3
18	C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. 1999 ·PubMed ·Peter C. Willsher, S Pinder, Julia M.W. Gee, Ian O. Ellis, Stephen Chan, Robert I. Nicholson, R.W. Blamey, J.F.R. Robertson	25
19	Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast 1993 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Kurt Werner Schmid, Ian O. Ellis, Julia M.W. Gee, (unknown), Wendy E. Lees, Jonathan Kay, Anthony Cryer, J. M. Stark, A Hittmair, Dietmar Öfner, Martina Dünser, R. Margreiter, G. Daxenbichler, R.I. Nicholson, Bert Bier, W. Böcker, Bharat Jasani	97
20	The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer 1993 ·European Journal of Cancer ·David L. Manning, R A McClelland, Julia M.W. Gee, Christina M.W. Chan, (unknown), R.W. Blamey, Robert I. Nicholson	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact